Amendment

SeaChange Announces an Amended Purchase Agreement with Partner One Along with an Increased Purchase Price as Go-Shop Period Ends

Retrieved on: 
Mercoledì, Aprile 10, 2024
Sale, LLP, OTC, FAST, New Purchase, Proxy, Amendment, Purchasing, SeaChange, Acquisition, Eastern Time Zone, SeaChange International, Advertising, Needham & Company, Disclosure

The New Purchase Price represents an increase of over $2 million compared to the previously announced asset sale (the “Previously Announced Asset Sale”) and is the only material detail of the Amended Asset Sale that differs from the Previously Announced Asset Sale.

Key Points: 
  • The New Purchase Price represents an increase of over $2 million compared to the previously announced asset sale (the “Previously Announced Asset Sale”) and is the only material detail of the Amended Asset Sale that differs from the Previously Announced Asset Sale.
  • The Company now expects the Amended Asset Sale will result in net proceeds to SeaChange of between $15-17 million upon Closing.
  • Also, SeaChange stockholders should please note that Proposal No.1 on the proxy card now refers to the Amended Asset Sale.
  • Needham & Company, LLC is acting as exclusive financial advisor to SeaChange in this transaction, and K&L Gates LLP is acting as legal counsel to SeaChange in this transaction.

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms

Retrieved on: 
Venerdì, Aprile 26, 2024
Software, Finance, Banking, Data Management, Accounting, Professional Services, Technology, Security, CP, FRR, European Parliament, Amendment, Wolters, Risk management, EHS, Capital Requirements Regulation 2013, ESG, CRD, GRC, Capital Requirements Directives, Risk

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe.

Key Points: 
  • The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe.
  • “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor.
  • Whereas other significant jurisdictions, including the U.S., the U.K. and Hong Kong, have deferred timelines, the EEA region is now moving ahead with the Basel III reforms without delay.
  • Wolters Kluwer FRR is part of Wolters Kluwer’s Corporate Performance & ESG (CP & ESG) division, headed by CEO Karen Abramson .

Ontrak Announces 2023 Fourth Quarter and Year End Financial Results

Retrieved on: 
Martedì, Aprile 16, 2024
Mental Health, Technology, Health Technology, Telemedicine, Virtual Medicine, Health Insurance, Software, Managed Care, General Health, Health, Artificial Intelligence, Well, OTRK, ROI, Acceleration, Amendment, Private, Fourth, Constitutional right, Partnership, Exchange, Quality, Research, Exercise, Public, Operating cost, Diagnosis, Sixth Amendment, Security (finance)

Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled healthcare company, today reported its financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled healthcare company, today reported its financial results for the fourth quarter and year ended December 31, 2023.
  • Operating loss for the fourth quarter of 2023 was $(5.2) million compared to an operating loss of $(8.0) million for the same period in 2022.
  • Adjusted EBITDA for the fourth quarter of 2023 was $(3.6) million compared to adjusted EBITDA of $(6.1) million for the same period in 2022.
  • Total enrolled members in our WholeHealth+ program numbered 1,758 at the end of Q4 2023, compared to 2,297 at the end of Q3 2023 and 1,333 at the end of Q4 2022.

Heliogen Extends Limited Duration Stockholders Rights Plan

Retrieved on: 
Martedì, Aprile 16, 2024
Technology, Mining, Minerals, Natural Resources, Other Energy, Commercial Building & Real Estate, Utilities, Construction & Property, Oil, Gas, Steel, Coal, Alternative Energy, Energy, Chemicals, Plastics, Nuclear, Manufacturing, Software, Artificial Intelligence, Chairperson, Dislocation, Amendment, Acquisition, Security (finance)

Heliogen, Inc. (“Heliogen” or the “Company”) (OTCQX: HLGN), a leading provider of AI-enabled concentrating solar energy technology, today announced that its Board of Directors (the “Board”) adopted an amendment to its existing limited duration stockholder rights plan (as amended, the “Rights Plan”) to extend the duration of the Rights Plan and reduce the exercise price of the rights.

Key Points: 
  • Heliogen, Inc. (“Heliogen” or the “Company”) (OTCQX: HLGN), a leading provider of AI-enabled concentrating solar energy technology, today announced that its Board of Directors (the “Board”) adopted an amendment to its existing limited duration stockholder rights plan (as amended, the “Rights Plan”) to extend the duration of the Rights Plan and reduce the exercise price of the rights.
  • The extension of the Rights Plan is intended to enable all of our stockholders to realize the long-term value of their investment, particularly in light of the Company’s previously announced consideration of strategic alternatives.
  • In addition, the Rights Plan does not prevent the Board from engaging with parties or accepting an acquisition proposal if the Board believes that it is in the best interests of Heliogen and all of its stockholders.
  • The Rights Plan, as amended, will automatically expire on April 17, 2025 unless the rights are earlier redeemed by the Company.

Turkiye Garanti Bankasi A.S.: Information regarding the results of Ordinary General Shareholders' Meeting

Retrieved on: 
Mercoledì, Aprile 10, 2024
Financial statement, Organization, Letter, Prejudice, Independent, Bank, Head, Record, Capital market, Domestic trade, Tax, Book, Amendment, Pension fund

The meeting minutes, list of participants and the profit distribution table are attached hereto.

Key Points: 
  • The meeting minutes, list of participants and the profit distribution table are attached hereto.
  • (The meeting minutes and the profit distribution table are in Turkish and English, whereas the list of participants is in Turkish.)
  • *In contradiction between the Turkish and English versions of this public disclosure, the Turkish version shall prevail.
  • Contact Garanti BBVA Investor Relations:

POLL: Ahead of National Beer Day, Tiger Woods Clinches Title as America’s Preferred Masters Champ to Share a Beer

Retrieved on: 
Giovedì, Aprile 4, 2024
BBQ, Culture, Tax, Amendment, Prohibition, Ageing, Public policy, History, Ice cream, Beer Institute, Master, Restaurant, GDP, Cheese, Beer, Legislation

According to NIQ, last year beer sales jumped 19% year-over-year in bars compared to 2022.

Key Points: 
  • According to NIQ, last year beer sales jumped 19% year-over-year in bars compared to 2022.
  • On National Beer Day, we celebrate the many ways that beer belongs in our history, culture and society.
  • Brewers Association, the Beer Institute is committed today to developing sound public policy and to the values of civic duty and personal responsibility.
  • For additional updates from the Beer Institute, visit our website and follow us on Facebook , X , LinkedIn and Instagram .

SiriusPoint Announces Pricing of Tender Offer for 4.600% Senior Notes due 2026

Retrieved on: 
Giovedì, Aprile 4, 2024
Tax, COVID-19, Acquisition, Security (finance), Insurance, Tender offer, Note, Expiration, Investment, Annual report, BMO Capital Markets, HSBC, Jefferies Group, Solicitation, Amendment, J.P. Morgan & Co.

Those who validly tender 2026 Notes and deliver consents before the Early Expiration Time will receive the Total Consideration for each $1,000 principal amount of accepted 2026 Notes.

Key Points: 
  • Those who validly tender 2026 Notes and deliver consents before the Early Expiration Time will receive the Total Consideration for each $1,000 principal amount of accepted 2026 Notes.
  • Those who validly tender 2026 Notes and deliver consents after the Early Expiration Time will receive the Total Consideration, less $50, for each $1,000 principal amount of accepted 2026 Notes.
  • The Tender Offer expires at 5:00 p.m., New York City time, on April 19, 2024, unless extended or earlier terminated by SiriusPoint (the “Tender Offer Expiration”).
  • SiriusPoint has further reserved the right, in its sole discretion, not to accept any tenders of 2026 Notes or deliveries of consents with respect to the 2026 Notes.

POET Technologies Announces Intention to Amend Warrant Terms

Retrieved on: 
Venerdì, Marzo 22, 2024
Indian stock exchange, TSX Venture Exchange, Exchange, Acceleration, The, Warrant, News, Die (integrated circuit), POET, Programmable interrupt controller, Amendment, Calendar, PTK, Security (finance)

Each Warrant is currently exercisable by the holder thereof to acquire one common share of the Corporation (each, a "Common Share") at an exercise price of C$4.95 (US$3.61) per Common Share until December 2, 2025.

Key Points: 
  • Each Warrant is currently exercisable by the holder thereof to acquire one common share of the Corporation (each, a "Common Share") at an exercise price of C$4.95 (US$3.61) per Common Share until December 2, 2025.
  • In accordance with the terms of the Warrants and the policies of the Exchange, the Corporation must obtain the consent of all holders of Warrants in order to give effect to the Amendments.
  • Upon the Amendments becoming effective, each Warrant will be exercisable until 5:00 p.m. (Toronto time) on December 2, 2025, at an exercise price of C$1.80 (US$1.33) per Common Share.
  • The amended warrant terms remain subject to the final acceptance of the Exchange.

GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update

Retrieved on: 
Giovedì, Aprile 4, 2024
Health, Neurology, Genetics, Pharmaceutical, Optical, Biotechnology, PIII, URD, Three-body problem, Patient, Good manufacturing practice, Health care, EAP, Acquisition, EMA, Risk, Chapter, GMP, MHRA, DS, ATU, AMF, Good, Phase, AAP, Ethics, FDA, Amendment, AAC, Medication, Pharmaceutical industry

GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.

Key Points: 
  • GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.
  • Once the AAC/AAP program resumes, the Company estimates that the cash runway would be extended to the end of Q1 2025.
  • GenSight successfully manufactured two Drug Substance (DS) batches of LUMEVOQ® meeting Good Manufacturing Practice (GMP) standards in September and November 2023.
  • As of March 31, 2024, GenSight Biologics’ number of outstanding shares was 78,370,724 ordinary shares.

GenSight Biologics Reports Full Year 2023 Consolidated Financial Results

Retrieved on: 
Venerdì, Marzo 22, 2024
Health, Neurology, Genetics, Pharmaceutical, Optical, Biotechnology, Control, URD, Three-body problem, Safety, Partnership, Research, CIR, ANSM, CMC, EMA, BofA Securities, Risk, Chapter, MHRA, Clinical trial, European Investment Bank, ATU, AMF, Workforce, EIB, AAP, Marketing, FDA, Amendment, AAC, Cryptocurrency

From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.

Key Points: 
  • From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.
  • The Company's general and administrative expenses also remained stable and amounted to €5.4 million in 2022 and 2023.
  • The weighted average number of shares outstanding increased from 46.3 million in 2022 to 48.3 million in 2023, thereby reducing the loss per share from (€0.54) in 2023 to (€0.60) in 2023.
  • GenSight Biologics will report its cash position as of March 31, 2024 on April 4 2024.